In a hemodynamically stable patient with a catheter‑associated bloodstream infection caused by ESBL‑producing Proteus mirabilis, is ertapenem 1 g IV daily appropriate as definitive therapy, and what are the recommended duration and monitoring steps?

Ertapenem for ESBL-Producing Proteus mirabilis Catheter-Associated Bloodstream Infection

Yes, ertapenem 1 g IV daily is appropriate as definitive therapy for a hemodynamically stable patient with catheter-associated bloodstream infection caused by ESBL-producing Proteus mirabilis. The recommended duration is 7-14 days after catheter removal, with mandatory follow-up blood cultures to document clearance.

Rationale for Ertapenem Use

Ertapenem is an excellent choice for this clinical scenario based on several key factors:

• Guideline-directed therapy: For gram-negative bacilli causing catheter-related bloodstream infections (CRBSI), the IDSA guidelines recommend 7-14 days of systemic antibiotic therapy after catheter removal 1. Carbapenems are the treatment of choice for ESBL-producing organisms 2.

• Proven efficacy in ESBL infections: Recent multicenter data demonstrates that ertapenem has comparable 30-day mortality rates to other carbapenems (meropenem, imipenem, doripenem) for ESBL-producing Enterobacterales bacteremia, with no significant difference even in patients with severe sepsis or septic shock 3. This is critical evidence supporting ertapenem's use in bloodstream infections.

• Specific experience with ESBL-Proteus: A case series showed 91% clinical efficacy and 85.7% microbiologic cure rates when ertapenem was used for ESBL-producing infections, including Proteus mirabilis 4. Importantly, carbapenems were associated with complete response in ESBL-positive Proteus mirabilis bloodstream infections 2.

Management Algorithm

1. Immediate Actions

• Remove the catheter promptly - This is non-negotiable for gram-negative CRBSI 1
• Culture the catheter tip (≥15 CFU by roll-plate method confirms catheter-related infection) 1
• Obtain at least 2 sets of blood cultures: one peripheral and one from the catheter before removal 1

2. Antibiotic Dosing

• Ertapenem 1 g IV once daily 5
• Adjust for renal function: If CrCl <30 mL/min, reduce to 500 mg IV daily 5
• Infuse over 30 minutes 5

3. Treatment Duration

• 7-14 days total from the first day of negative blood cultures (day 1 = first negative culture) 1
• Use 7 days for uncomplicated infection (fever resolves within 72 hours, no evidence of endocarditis or thrombophlebitis, hemodynamically stable)
• Use 14 days if any complications present or if bacteremia persists >72 hours despite appropriate therapy

4. Mandatory Monitoring Steps

Within 72 hours:

• Assess clinical response (defervescence, hemodynamic stability, resolution of sepsis)
• If fever persists >72 hours despite appropriate therapy, obtain repeat blood cultures and evaluate for:
  • Suppurative thrombophlebitis
  • Endocarditis (obtain echocardiography if S. aureus or persistent bacteremia)
  • Metastatic foci of infection
  • Retained catheter material

Follow-up blood cultures:

• Obtain repeat blood cultures 2-4 days after starting therapy to document clearance 1
• Critical: If blood cultures remain positive >72 hours after catheter removal and appropriate antibiotics, extend therapy to at least 4 weeks and investigate for endocarditis 1

At completion of therapy:

• While routine post-treatment blood cultures are not mandated by guidelines, consider them in this case given the ESBL pathogen 1

5. Monitor for Complications

• Clostridioides difficile infection: Monitor for diarrhea within 90 days (though ertapenem shows no increased risk compared to other carbapenems) 3
• Emergence of carbapenem resistance: While rare, one case series reported development of ertapenem-resistant E. coli during therapy 4

Important Caveats

When NOT to use ertapenem:

• If patient becomes hemodynamically unstable or develops severe sepsis/septic shock requiring ICU admission - though recent evidence suggests ertapenem remains effective even in these scenarios 3
• If Pseudomonas aeruginosa, Acinetobacter, or Enterococcus co-infection is suspected (ertapenem lacks activity against these organisms) 6
• If patient is critically ill with high body mass index (>30 kg/m²) - consider extended infusion or alternative carbapenem due to pharmacokinetic concerns 6

Advantages of ertapenem over other carbapenems:

• Once-daily dosing improves compliance and allows outpatient parenteral therapy if appropriate
• Lower risk of "collateral damage" (selection pressure for resistant organisms) 6
• Comparable efficacy to meropenem/imipenem with potentially better antimicrobial stewardship profile 3

Key pitfall to avoid: Do not retain the catheter in gram-negative CRBSI. Unlike coagulase-negative staphylococci where salvage may be attempted, gram-negative bacilli require catheter removal for optimal outcomes 1.